Fatma Demir Yenigürbüz

Fatma Demir Yenigürbüz

Auto-generated profile, based on publicly available information

Fatma Demir Yenigürbüz

Department of Pediatric Hematooncology, Department of Medical Sciences Pediatric Health And Diseases, School of Medicine, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Turkish Journal of Hematology
Verified
Journal Article
Open access
DKDeniz Kızmazoğlu
Deniz Kızmazoğlu
SSSeher Sarı
Seher Sarı
MEMelike Sezgin Evim
Melike Sezgin Evim
AKArzu Çırpan Kantarcıoğlu
Arzu Çırpan Kantarcıoğlu
ÖTÖzlem Tüfekçi
Özlem Tüfekçi
HÖHale Ören
Hale Ören
We investigated the health-related quality of life (HRQL) in survivors of pediatric acute lymphoblastic leukemia (ALL) and evaluated the perceptions of the children, their siblings, and their parents. Seventy ALL survivors, who were between 7 and 17 years of age and had completed therapy ≥2 years, were included. The control group consisted of their healthy siblings. HRQL was assessed by the age-specific KINDLR questionnaire. No significant differences could be found among HRQL scores of ALL survivors with respect to variables such as sex, risk group, and having chronic illness. HRQL scores for physical well-being, emotional well-being, family, and social functioning of the patient and sibling self-reports and parent proxy reports were lower than the expected values for healthy and chronically ill children. These results demonstrate that both ALL survivors and their families need help via psychological counseling programs to improve their HRQL even after completion of therapy.

4 March 2022 in Hemoglobin
Verified
Journal Article
Closed access
YBYüksel Bıcılıoğlu
Yüksel Bıcılıoğlu
ABAlkan Bal
Alkan Bal
FYFatma Demir Yenigürbüz
Fatma Demir Yenigürbüz
EEEsin Ergonul
Esin Ergonul
SGSüleyman Geter
Süleyman Geter
UBUfuk Bal
Ufuk Bal
This study was conducted to investigate the agreement between laboratory hemoglobin (LabHb) measured in venous blood and noninvasive, spectrophotometric hemoglobin (SpHb) measurement and the usability of SpHb measurement in the transfusion decision-making in patients with thalassemia whose hemoglobin (Hb) was monitored by taking blood samples at frequent intervals and who were transfused. Cardiac pulse, oxygen saturation, Pleth variability index (PVI), and SpHb values were measured in patients who came to the hematology outpatient clinic for a control visit and whose Hb levels were planned to be measured. Venous blood samples were taken for LabHb measurement, which we accept as the gold standard. Cohen’s kappa value was calculated for the agreement between SpHb measurements and LabHb values. The relationship and predictability between both measurement methods were evaluated by Pearson correlation analysis, a modified Bland-Altman plot and the linear regression model. In the study conducted with a total of 110 children with thalassemia, a moderate level of agreement between the two measurement methods (kappa = 0.370, p < 0.0001) and a significantly high correlation between the two tests (r = 0.675) were found. The mean bias between the differences was found to be 0.3 g/dL (–1.27 to 1.86 g/dL). The sensitivity and the specificity of SpHb in identifying patients who needed transfusions (Hb <10.0 g/dL) were calculated as 92.2 and 57.1%, respectively. Our results suggest SpHb measurement may be used to screen anemia in hemodynamically stable hemoglobinopathy patients and even for transfusion decision-making with combination clinical findings.

7 August 2023 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
ÇGÇiğdem Çetin Genç
Çiğdem Çetin Genç
CGCelal Genç
Celal Genç
FYFatma Demir Yenigürbüz
Fatma Demir Yenigürbüz


27 December 2022 in Harran Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
FYFatma Demi̇r Yeni̇gurbuz
Fatma Demi̇r Yeni̇gurbuz
BABurcu Akinci
Burcu Akinci
AÜAla Üstyol
Ala Üstyol
DÖDeniz Ökdemi̇r
Deniz Ökdemi̇r
ASAhmet Sezer
Ahmet Sezer
Background: Our aim was to identify risk factors and clinical correlates of endocrine complications in β-thalassemia major (BTM) patients. Materials and methods: This was a retrospective study carried out in the pediatric hematology and pediatric endocrinology departments of a tertiary healthcare institution with the medical data of 249 children with BTM (108 females, 43.4%; 141 males, 56.6%) with a median age of 7.17 (2 -17.8) years. Baseline descriptive, clinical features including endocrine complications and laboratory data were noted. Correlation between the presence of endocrine complications and demographic, clinical, and laboratory variables were sought. The effects of age, gender, race, height, weight, and splenectomy on endocrine complications were evaluated separately in each complication group. Results: Vitamin D deficiency/insufficiency is the most common endocrine complication (41.7%). According to Turkish children, Syrian children had also significantly lower vitamin D concentration (p=0.001). At least one endocrinopathy was reported in the majority of BTM patients (67.9%). Accordingly, pubertal status (p=0.014) and Syrian nationality (p=0.007) had significant impacts on TSH levels. Syrian children and those with delayed puber-ty had greater likelihood for subclinical or evident hypothyroidism. The likelihood of suffering from at least one endocrine complication was higher in older children (p=0.042) and those with Syrian nationality (p=0.025) Conclusion: Disorders of endocrine and metabolic nature are common in children with BTM. Early detection and protocol-based multidisciplinary management of these disorders constitute the most suitable strategies to in-crease patients' quality of life. Surveillance, early detection and treatment, and collaborative follow-up with a multidisciplinary team are the key points in the reduction of the severity and frequency of endocrine complica-tions as well as optimization of therapeutic outcomes.